[go: up one dir, main page]

MX2018011951A - Metodo para seleccionar proteinas recombinantes ricas en m6p. - Google Patents

Metodo para seleccionar proteinas recombinantes ricas en m6p.

Info

Publication number
MX2018011951A
MX2018011951A MX2018011951A MX2018011951A MX2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A MX 2018011951 A MX2018011951 A MX 2018011951A
Authority
MX
Mexico
Prior art keywords
recombinant human
selection
human lysosomal
lysosomal proteins
recombinant proteins
Prior art date
Application number
MX2018011951A
Other languages
English (en)
Inventor
Gotschall Russell
V Do Hung
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2018011951A publication Critical patent/MX2018011951A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Water Supply & Treatment (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para producir, capturar y purificar proteínas lisosomales humanas recombinantes. Estas proteínas lisosomales humanas recombinantes pueden tener un contenido elevado de residuos de manosa-6-fosfato. Composiciones farmacéuticas que comprenden estas proteínas lisosomales humanas recombinantes. Métodos de tratamiento. Usos de estas proteínas lisosomales humanas recombinantes.
MX2018011951A 2016-03-30 2017-03-30 Metodo para seleccionar proteinas recombinantes ricas en m6p. MX2018011951A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662315400P 2016-03-30 2016-03-30
US201762457584P 2017-02-10 2017-02-10
US15/473,994 US10227577B2 (en) 2016-03-30 2017-03-30 Method for selection of high M6P recombinant proteins
PCT/US2017/024981 WO2017173059A1 (en) 2016-03-30 2017-03-30 Method for selection of high m6p recombinant proteins

Publications (1)

Publication Number Publication Date
MX2018011951A true MX2018011951A (es) 2019-02-13

Family

ID=58640993

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018011951A MX2018011951A (es) 2016-03-30 2017-03-30 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014532A MX2022014532A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014533A MX2022014533A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022014532A MX2022014532A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2022014533A MX2022014533A (es) 2016-03-30 2018-09-28 Metodo para seleccionar proteinas recombinantes ricas en m6p.

Country Status (13)

Country Link
US (3) US10227577B2 (es)
JP (3) JP7046003B2 (es)
KR (4) KR102455821B1 (es)
AU (3) AU2017239640B2 (es)
CA (1) CA3019354A1 (es)
CL (1) CL2018002767A1 (es)
IL (3) IL262060B (es)
MX (3) MX2018011951A (es)
NZ (1) NZ786723A (es)
PE (1) PE20190127A1 (es)
SG (1) SG11201808592PA (es)
WO (1) WO2017173059A1 (es)
ZA (2) ZA201807184B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY198085A (en) 2015-12-30 2023-07-31 Amicus Therapeutics Inc Augmented acid alpha-glucosidase for the treatment of pompe disease
KR102618519B1 (ko) * 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
US10227577B2 (en) * 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
EP3568152A1 (en) * 2017-01-10 2019-11-20 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a for treatment of fabry disease
HRP20230576T1 (hr) 2017-05-15 2023-09-01 Amicus Therapeutics, Inc. Rekombinantna ljudska kisela alfa-glukozidaza
EA202190416A1 (ru) 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
GB201911686D0 (en) 2019-08-15 2019-10-02 Fujifilm Diosynth Biotechnologies Uk Ltd Process for purifying target substances
WO2021046443A1 (en) * 2019-09-06 2021-03-11 Amicus Therapeutics, Inc. Method for capturing and purification of biologics
EP4077357B1 (en) * 2019-12-17 2023-09-06 Navigo Proteins Gmbh Binding proteins for the enzyme acid alpha glucosidase (gaa) and uses thereof
EP3871687A1 (en) * 2020-02-27 2021-09-01 eleva GmbH Enzyme replacement therapy for treating pompe disease
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
JP2025515159A (ja) 2022-05-05 2025-05-13 アミカス セラピューティックス インコーポレイテッド ポンペ病の治療方法
AU2023406479A1 (en) 2022-12-02 2025-07-03 Amicus Therapeutics, Inc. Methods for treating late onset pompe disease in pediatric patients
TW202436620A (zh) 2022-12-02 2024-09-16 美商阿米庫斯醫療股份有限公司 用於在兒科患者中治療嬰兒型龐貝氏症之方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US20020073438A1 (en) * 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US20020013953A1 (en) * 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
DK1030839T3 (da) 1997-11-10 2004-05-03 Searle & Co Anvendelse af alkylerede iminosukkere til behandling af multidrugresistens
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2020438B1 (en) 1998-12-07 2018-04-11 Genzyme Corporation Treatment of pompe's disease
ES2311921T3 (es) 1999-02-12 2009-02-16 United Therapeutics Corporation N-(8,8,8-trifluorooctil)1-5,-didesoxi-1,5-imino-d-glucitol para tratar infecciones por el virus de la hepatitis.
ATE234626T1 (de) 1999-07-26 2003-04-15 Searle & Co Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
DK2767291T3 (en) 2000-07-18 2016-12-05 Univ Duke Treatment of glycogen storage disease type II
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
DE60224816T2 (de) 2001-04-30 2009-01-22 ZyStor Therapeutics, Inc., Milwaukee Subzelluläres targeting von therapeutischen proteinen
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
MXPA04003640A (es) 2001-10-16 2005-04-11 Rxkinetix Inc Formulaciones de proteina de alta concentracion y metodo de fabricacion.
WO2003086452A2 (en) 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
ES2686775T3 (es) 2003-01-31 2018-10-19 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2005211775B2 (en) 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
AU2005212435B2 (en) 2004-02-10 2010-09-09 Biomarin Pharmaceutical Inc. Acid alpha-glucosidase and fragments thereof
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
MX2007014470A (es) * 2005-05-17 2008-02-06 Amicus Therapeutics Inc Metodo para el tratamiento de enfermedad de pompe usando derivados de 1-desoxinojirimicina.
CA2669347A1 (en) 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
EP2155197A4 (en) 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
US9056101B2 (en) 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US20100317690A1 (en) 2007-11-21 2010-12-16 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
HUE042882T2 (hu) * 2008-02-12 2019-07-29 Amicus Therapeutics Inc Eljárás betegségek farmakológiai chaperonnal történõ kezelésére adott válasz elõrejelzésére
MX2010009874A (es) 2008-03-12 2010-11-30 Amicus Therapeutics Inc Tratamiento para la enfermedad de pompe con chaperonas farmacologicas especificas y monitoreo del tratamiento usando marcadores subrogados.
JP2011517556A (ja) 2008-03-12 2011-06-16 アミカス セラピューティックス インコーポレイテッド ポンペ病のための治療選択肢を診断し評価するための検定
EP2323652A2 (en) 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010056746A1 (en) 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
HUE044381T2 (hu) 2008-12-16 2019-10-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához
ES2564093T3 (es) 2009-04-09 2016-03-17 Amicus Therapeutics, Inc. Métodos para prevenir y/o tratar trastornos del almacenamiento lisosomal
EP3679942A1 (en) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
CN102712914A (zh) * 2009-09-29 2012-10-03 根特大学 水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
US9347050B2 (en) * 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
JP2014513952A (ja) 2011-04-22 2014-06-19 ジェンザイム・コーポレーション 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
KR102076585B1 (ko) 2011-12-22 2020-02-12 센토제너 아이피 게엠베하 리소좀 효소를 재배열하는 능력을 갖는 화합물 및 암브록솔 및/또는 암브록솔의 유도체의 조합물
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
RU2644258C2 (ru) 2012-03-15 2018-02-08 Оксирейн Юкей Лимитед Способы и материалы для лечения болезни помпе
SMT202100136T1 (it) 2012-05-03 2021-05-07 Amicus Therapeutics Inc Regimi posologici per il trattamento della malattia di pompe
CA2915127A1 (en) 2012-06-06 2013-12-12 Giancarlo PARENTI Allosteric chaperones and uses thereof
CA2961762C (en) 2014-09-30 2024-03-05 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US10227577B2 (en) * 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins

Also Published As

Publication number Publication date
US20190382742A1 (en) 2019-12-19
KR20250050123A (ko) 2025-04-14
PE20190127A1 (es) 2019-01-17
US10227577B2 (en) 2019-03-12
MX2022014532A (es) 2022-12-13
IL262060A (en) 2018-11-29
JP7436545B2 (ja) 2024-02-21
JP7046003B2 (ja) 2022-04-01
AU2022259797A1 (en) 2022-12-01
MX2022014533A (es) 2022-12-13
AU2017239640A1 (en) 2018-10-25
SG11201808592PA (en) 2018-10-30
IL295551A (en) 2022-10-01
US20170335301A1 (en) 2017-11-23
AU2022259797B2 (en) 2024-08-08
NZ786723A (en) 2025-07-25
AU2024259782A1 (en) 2024-11-28
KR102343162B1 (ko) 2021-12-23
US11441138B2 (en) 2022-09-13
IL262060B (en) 2022-09-01
CA3019354A1 (en) 2017-10-05
KR102455821B1 (ko) 2022-10-18
US20230079225A1 (en) 2023-03-16
JP2024063015A (ja) 2024-05-10
ZA202006604B (en) 2023-04-26
CL2018002767A1 (es) 2019-01-11
AU2017239640B2 (en) 2022-07-28
JP2019509754A (ja) 2019-04-11
JP2022101545A (ja) 2022-07-06
KR20180128945A (ko) 2018-12-04
WO2017173059A1 (en) 2017-10-05
NZ746768A (en) 2025-05-02
IL319770A (en) 2025-05-01
KR20210157477A (ko) 2021-12-28
IL295551B1 (en) 2025-04-01
ZA201807184B (en) 2021-02-24
KR102790256B1 (ko) 2025-04-04
IL295551B2 (en) 2025-08-01
KR20220145918A (ko) 2022-10-31
BR112018070189A2 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
MX2018011951A (es) Metodo para seleccionar proteinas recombinantes ricas en m6p.
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EA201792649A1 (ru) Способы кондиционирования пациентов для t-клеточной терапии
MX385845B (es) Usos y composiciones de la flagelina
EA201890111A1 (ru) Замещенные производные оксопиридина
BR112014028476A2 (pt) fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
EA201791095A1 (ru) Способ лечения рака
MX2020005446A (es) Metodos para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento.
BR112017017727A2 (pt) heterociclos bicíclicos como inibidores de fgfr4
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
MX2018002344A (es) Metodo para tratar el cancer.
MX2016008448A (es) Conjugados de var2csa-farmaco.
EA202090683A3 (ru) Способы и композиции для лечения рака
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
EA201390676A1 (ru) Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза
NZ710602A (en) Methods for reducing pyrogenicity in a seaweed extract
BR112017019728A2 (pt) combinações e formulações de dose fixa compreendendo etc1002 e uma ou mais estatinas e método para tratar ou reduzir o risco de doença cardiovascular
MX379510B (es) Coronavirus bovino atenuado y vacunas relacionadas.
MY174991A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
BR112016010072A8 (pt) conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado